Clinical characteristics of major ABO-incompatible nonmyeloablative stem cell transplant patients
| UPN and diagnosis . | ABO D → R (titer)* . | Cell dose CD34/CD3† . | Anti-GVHD . | Serologic and molecular chimerism data (d)‡ . | Acute GVHD Gr/(d) . | Response,1-153 status1-155 (d) . | |||
|---|---|---|---|---|---|---|---|---|---|
| First donor RBC . | Host isohemagglutinin ≤ 1+ . | 100% donor T cell . | 100% donor myeloid . | ||||||
| First donor RBC chimerism after day 100 (n = 9) | |||||||||
| Pure red cell aplasia (n = 4) | |||||||||
| 113 RCC | A → O (NT) | 5.9/151 | CsA | 174 | 188 | 14 | 60 | II/78 | PR, D(699) |
| 138 CML | A → O (NT) | 15/533 | CsA | 188 | 128 | 14 | 14 | None | CR, RL, D(415) |
| 149 PNH | A → O (1024) | 21/445 | CsA | 134 | 144 | 30 | 30 | None | CR, A(544) |
| 178 SAA | A → O (256) | 3.5/389 | CsA | 218 | 222 | 14 | 30 | I/27 | CR, A(425) |
| Median values | 10/417 | 181 | 166 | 14 | 30 | ||||
| No pure red cell aplasia (n = 5) | |||||||||
| 159 RCC | AB → A (16) | 2.6/476 | CsA | 116 | 53 | 12 | 145 | None | NR, D(193) |
| 192 RCC | B → O (16) | 14/300 | CsA | 113+ | 35 | 47 | 97+ | IV/20 | NR, D(126) |
| 193 RCC1-154 | A → O (128) | 7.4/363 | CsA | 113+ | 113+ | 30 | 97 | None | NR, D(116) |
| 215 Sarc | A → O (64) | 7.3/265 | CsA/MMF | 130 | 183+ | 99 | 220+ | None | NR, D(229) |
| 216 RCC | B → A (64) | 4.3/206 | CsA/MMF | 125 | 119 | 13 | 65 | II/115 | PR, A(246) |
| Median values | 5.9/332 | 116 | 113 | 30 | 97 | ||||
| First donor RBC chimerism before day 100 (n = 5) | |||||||||
| 115 CML | B → O (NT) | 3.7/351 | CsA | 16+ | 16+ | 30 | 90 | II/30 | CR, A(749) |
| 118 MM | A → O (NT) | 6.4/333 | CsA | 47+ | 47+ | 21 | 100 | None | PR, A(711) |
| 198 Sarc | B → O (8) | 18/363 | CsA | 47 | 19 | 14 | 30 | None | NR, D(118) |
| 201 RCC1-159 | B → O (32) | 5.1/290 | CsA | 60 | 17 | 14 | 14 | IV/15 | NR, D(158) |
| 222 CLL | A → O (NT) | 4.0/153 | CsA/MMF | 28 | 28 | 30 | 146+ | None | NR, D(146) |
| Median values | 5.8/312 | 47 | 19 | 30 | 100 | ||||
| ALL NSTs (n = 14)1-160 | 6.2/342 | 114 | 83 | 21 | 81 | 6A, 8D(209) | |||
| UPN and diagnosis . | ABO D → R (titer)* . | Cell dose CD34/CD3† . | Anti-GVHD . | Serologic and molecular chimerism data (d)‡ . | Acute GVHD Gr/(d) . | Response,1-153 status1-155 (d) . | |||
|---|---|---|---|---|---|---|---|---|---|
| First donor RBC . | Host isohemagglutinin ≤ 1+ . | 100% donor T cell . | 100% donor myeloid . | ||||||
| First donor RBC chimerism after day 100 (n = 9) | |||||||||
| Pure red cell aplasia (n = 4) | |||||||||
| 113 RCC | A → O (NT) | 5.9/151 | CsA | 174 | 188 | 14 | 60 | II/78 | PR, D(699) |
| 138 CML | A → O (NT) | 15/533 | CsA | 188 | 128 | 14 | 14 | None | CR, RL, D(415) |
| 149 PNH | A → O (1024) | 21/445 | CsA | 134 | 144 | 30 | 30 | None | CR, A(544) |
| 178 SAA | A → O (256) | 3.5/389 | CsA | 218 | 222 | 14 | 30 | I/27 | CR, A(425) |
| Median values | 10/417 | 181 | 166 | 14 | 30 | ||||
| No pure red cell aplasia (n = 5) | |||||||||
| 159 RCC | AB → A (16) | 2.6/476 | CsA | 116 | 53 | 12 | 145 | None | NR, D(193) |
| 192 RCC | B → O (16) | 14/300 | CsA | 113+ | 35 | 47 | 97+ | IV/20 | NR, D(126) |
| 193 RCC1-154 | A → O (128) | 7.4/363 | CsA | 113+ | 113+ | 30 | 97 | None | NR, D(116) |
| 215 Sarc | A → O (64) | 7.3/265 | CsA/MMF | 130 | 183+ | 99 | 220+ | None | NR, D(229) |
| 216 RCC | B → A (64) | 4.3/206 | CsA/MMF | 125 | 119 | 13 | 65 | II/115 | PR, A(246) |
| Median values | 5.9/332 | 116 | 113 | 30 | 97 | ||||
| First donor RBC chimerism before day 100 (n = 5) | |||||||||
| 115 CML | B → O (NT) | 3.7/351 | CsA | 16+ | 16+ | 30 | 90 | II/30 | CR, A(749) |
| 118 MM | A → O (NT) | 6.4/333 | CsA | 47+ | 47+ | 21 | 100 | None | PR, A(711) |
| 198 Sarc | B → O (8) | 18/363 | CsA | 47 | 19 | 14 | 30 | None | NR, D(118) |
| 201 RCC1-159 | B → O (32) | 5.1/290 | CsA | 60 | 17 | 14 | 14 | IV/15 | NR, D(158) |
| 222 CLL | A → O (NT) | 4.0/153 | CsA/MMF | 28 | 28 | 30 | 146+ | None | NR, D(146) |
| Median values | 5.8/312 | 47 | 19 | 30 | 100 | ||||
| ALL NSTs (n = 14)1-160 | 6.2/342 | 114 | 83 | 21 | 81 | 6A, 8D(209) | |||
Donors were HLA-identical siblings except for a B-locus mismatch, and a DR-locus mismatch, indicated by footnotes below.
UPN indicates unique patient number; GVHD, graft-versus-host disease; d, day of event; RBC, red blood cell; Gr, maximum grade acute GVHD; RCC, renal cell carcinoma; CML, chronic myelogenous leukemia; PNH, paroxysmal nocturnal hemoglobinuria; SAA, aplastic anemia; Sarc, high-grade metastatic soft-tissue sarcoma; CsA, cyclosporine; MM, multiple myeloma; CLL, chronic lymphocytic leukemia; NST, nonmyeloablative stem cell transplant; NT, not tested; MMF, mycophenolate mofetil.
Donor → recipient ABO group (recipient titer against relevant donor ABO antigen).
Cell dose is 106/kg.
A plus sign indicates censored data point.
Response: CR indicates complete response, PR, partial response; RL, relapse; NR, no response.
Status: A indicates alive; D, dead.
Donor was a B-locus mismatch.
Donor was a DR mismatch.
Totals are median values.